These findings align with conventional and genetic epidemiological evidence suggesting the potential adverse effects of select antihypertensive agents (ie, ACE [angiotensin-converting enzyme inhibitors]) on cancer risk, though mechanisms accounting for these associations remain unclear.60,61 Further functional work is required to validate these findings to elucidate mechanisms accounting for opposing effects across CAD and cancer risk. This evidence concerns the gene ACE and coronary artery disorder.